Initial Experience With Lung Cancer Resection After Treatment With T-Cell Checkpoint Inhibitors.
case_series · Level IV
Where this comes from
- Record sourced from PubMed, PMID 28838509.
- Also identified by DOI 10.1016/j.athoracsur.2017.03.038 and PMC identifier 5572805.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
T-cell checkpoint inhibitors targeting the programmed death receptor-1 (PD-1) and its ligand (PD-L1) have recently been approved for the treatment of metastatic non-small cell lung cancer (NSCLC), but their safety and efficacy as neoadjuvant therapy are still undefined. Autoimmune toxicities, notably pneumonitis, are a particular concern in the perioperative setting. This series of 5 cases describes for the first time the safety and technical issues relating to pulmonary resection after checkpoint inhibitor therapy.
Medical subject headings
- Antibodies, Monoclonal
- Antineoplastic Agents
- Carcinoma, Non-Small-Cell Lung
- Immunologic Factors
- Lung Neoplasms